Targeting an HIV-1 nef-host cell kinase complex

A method for treating HIV-1 in a subject in need thereof, comprising (a) identifying a subject infected with HIV-1 and then (b) administering to said subject a therapeutic dose of a Formula I compound

• wherein
• Cy1 is selected from the group consisting of aryl and heteroaryl, wherein the aryl or heteroaryl group is optionally substituted with one or more members selected from the group consisting of —OH, chloroacetyl halogen, sulfonic acid, nitro and —O-alkyl;
• Cy2 is an aryl optionally substituted with one or more members selected from the group consisting of halogen, alkyl, amino and —O-alkyl;
• R5, R6, R7, and R8 are independently selected from the group consisting of hydrogen and —OR11, and
• R11 is selected from the group consisting of optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl.